vida: extract claims from 2026-04-22-kff-medicaid-glp1-coverage-13-states

- Source: inbox/queue/2026-04-22-kff-medicaid-glp1-coverage-13-states.md
- Domain: health
- Claims: 1, Entities: 0
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp-1-access-structure-inverts-need-creating-equity-paradox.md

@@ -10,17 +10,18 @@ agent: vida
 scope: structural
 sourcer: The Lancet
 related_claims: ["[[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]", "[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]", "[[SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action]]"]
-supports:
+supports: ["GLP-1 access follows systematic inversion where states with highest obesity prevalence have both lowest Medicaid coverage rates and highest income-relative out-of-pocket costs", "Wealth stratification in GLP-1 access creates a disease progression disparity where lowest-income Black patients receive treatment at BMI 39.4 versus 35.0 for highest-income patients"]
-- GLP-1 access follows systematic inversion where states with highest obesity prevalence have both lowest Medicaid coverage rates and highest income-relative out-of-pocket costs
+challenges: ["Medicaid coverage expansion for GLP-1s reduces racial prescribing disparities from 49 percent to near-parity because insurance policy is the primary structural driver not provider bias"]
-- Wealth stratification in GLP-1 access creates a disease progression disparity where lowest-income Black patients receive treatment at BMI 39.4 versus 35.0 for highest-income patients
+reweave_edges: ["GLP-1 access follows systematic inversion where states with highest obesity prevalence have both lowest Medicaid coverage rates and highest income-relative out-of-pocket costs|supports|2026-04-14", "Medicaid coverage expansion for GLP-1s reduces racial prescribing disparities from 49 percent to near-parity because insurance policy is the primary structural driver not provider bias|challenges|2026-04-14", "Wealth stratification in GLP-1 access creates a disease progression disparity where lowest-income Black patients receive treatment at BMI 39.4 versus 35.0 for highest-income patients|supports|2026-04-14"]
-challenges:
+related: ["glp-1-access-structure-inverts-need-creating-equity-paradox", "glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost", "wealth-stratified-glp1-access-creates-disease-progression-disparity-with-lowest-income-black-patients-treated-at-13-percent-higher-bmi", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence", "glp-1-population-mortality-impact-delayed-20-years-by-access-and-adherence-constraints"]
-- Medicaid coverage expansion for GLP-1s reduces racial prescribing disparities from 49 percent to near-parity because insurance policy is the primary structural driver not provider bias
-reweave_edges:
-- GLP-1 access follows systematic inversion where states with highest obesity prevalence have both lowest Medicaid coverage rates and highest income-relative out-of-pocket costs|supports|2026-04-14
-- Medicaid coverage expansion for GLP-1s reduces racial prescribing disparities from 49 percent to near-parity because insurance policy is the primary structural driver not provider bias|challenges|2026-04-14
-- Wealth stratification in GLP-1 access creates a disease progression disparity where lowest-income Black patients receive treatment at BMI 39.4 versus 35.0 for highest-income patients|supports|2026-04-14
 ---
 
 # GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations
 
-The Lancet frames the GLP-1 equity problem as structural policy failure, not market failure. Populations most likely to benefit from GLP-1 drugs—those with high cardiometabolic risk, high obesity prevalence (lower income, Black Americans, rural populations)—face the highest access barriers through Medicare Part D weight-loss exclusion, limited Medicaid coverage, and high list prices. This creates an inverted access structure where clinical need and access are negatively correlated. The timing is significant: The Lancet's equity call comes in February 2026, the same month CDC announces a life expectancy record, creating a juxtaposition where aggregate health metrics improve while structural inequities in the most effective cardiovascular intervention deepen. The access inversion is not incidental but designed into the system—insurance mandates exclude weight loss, generic competition is limited to non-US markets (Dr. Reddy's in India), and the chronic use model makes sustained access dependent on continuous coverage. The cardiovascular mortality benefit demonstrated in SELECT, SEMA-HEART, and STEER trials will therefore disproportionately accrue to insured, higher-income populations with lower baseline risk, widening rather than narrowing health disparities.
+The Lancet frames the GLP-1 equity problem as structural policy failure, not market failure. Populations most likely to benefit from GLP-1 drugs—those with high cardiometabolic risk, high obesity prevalence (lower income, Black Americans, rural populations)—face the highest access barriers through Medicare Part D weight-loss exclusion, limited Medicaid coverage, and high list prices. This creates an inverted access structure where clinical need and access are negatively correlated. The timing is significant: The Lancet's equity call comes in February 2026, the same month CDC announces a life expectancy record, creating a juxtaposition where aggregate health metrics improve while structural inequities in the most effective cardiovascular intervention deepen. The access inversion is not incidental but designed into the system—insurance mandates exclude weight loss, generic competition is limited to non-US markets (Dr. Reddy's in India), and the chronic use model makes sustained access dependent on continuous coverage. The cardiovascular mortality benefit demonstrated in SELECT, SEMA-HEART, and STEER trials will therefore disproportionately accrue to insured, higher-income populations with lower baseline risk, widening rather than narrowing health disparities.
+
+## Extending Evidence
+
+**Source:** KFF Medicaid GLP-1 analysis, January 2026
+
+Nearly 4 in 10 adults and a quarter of children with Medicaid have obesity, representing tens of millions of potentially eligible beneficiaries. Yet only 13 states (26%) cover GLP-1s for obesity as of January 2026, and four states actively eliminated existing coverage in 2025-2026. The population with highest obesity burden and least ability to pay out-of-pocket faces the most restrictive access, with eligibility now depending primarily on state of residence rather than clinical need.

domains/health/medicaid-glp1-coverage-reversing-through-state-budget-pressure.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: Budget-driven coverage elimination represents a countertrend to the expansion narrative, creating geographic access fragmentation
+confidence: experimental
+source: KFF Medicaid analysis, January 2026
+created: 2026-04-22
+title: State Medicaid budget pressure is actively reversing GLP-1 obesity coverage gains with California and three other states eliminating coverage in 2025-2026
+agent: vida
+sourced_from: health/2026-04-22-kff-medicaid-glp1-coverage-13-states.md
+scope: structural
+sourcer: KFF
+supports: ["glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation"]
+related: ["federal-budget-scoring-methodology-systematically-undervalues-preventive-interventions-because-10-year-window-excludes-long-term-savings", "glp-1-access-structure-inverts-need-creating-equity-paradox", "glp-1-receptor-agonists-are-the-largest-therapeutic-category-launch-in-pharmaceutical-history-but-their-chronic-use-model-makes-the-net-cost-impact-inflationary-through-2035", "glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost"]
+---
+
+# State Medicaid budget pressure is actively reversing GLP-1 obesity coverage gains with California and three other states eliminating coverage in 2025-2026
+
+As of January 2026, only 13 states (26% of state programs) cover GLP-1s for obesity under fee-for-service Medicaid, but critically, four states have actively eliminated existing coverage due to budget pressure: California, New Hampshire, Pennsylvania, and South Carolina. California's Medi-Cal projected costs illustrate the mechanism: $85M in FY2025-26 rising to $680M by 2028-29—an 8x increase in three years. This cost trajectory drove California, the nation's largest Medicaid program, to eliminate coverage effective 2026 despite clear clinical benefit. The reversal is occurring concurrent with federal expansion attempts (BALANCE Model launching May 2026), creating a bifurcated landscape where some states expand while others actively cut. This is not coverage stagnation but active reversal—states that previously provided access are removing it. The mechanism is explicit: budget constraints override clinical benefit logic in state-level coverage decisions. GLP-1 spending grew from ~$1B (2019) to ~$9B (2024) in Medicaid, now representing >8% of total prescription drug spending despite being only 1% of prescriptions, making the budget pressure acute and driving elimination decisions.

domains/health/vbc-requires-enrollment-stability-as-structural-precondition-because-prevention-roi-depends-on-multi-year-attribution.md

@@ -10,14 +10,18 @@ agent: vida
 scope: structural
 sourcer: KFF Health News / CBO
 related_claims: ["[[the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness]]", "[[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk]]"]
-supports:
+supports: ["OBBBA Medicaid work requirements destroy the enrollment stability that value-based care requires for prevention ROI by forcing all 50 states to implement 80-hour monthly work thresholds by December 2026"]
-- OBBBA Medicaid work requirements destroy the enrollment stability that value-based care requires for prevention ROI by forcing all 50 states to implement 80-hour monthly work thresholds by December 2026
+reweave_edges: ["OBBBA Medicaid work requirements destroy the enrollment stability that value-based care requires for prevention ROI by forcing all 50 states to implement 80-hour monthly work thresholds by December 2026|supports|2026-04-09"]
-reweave_edges:
+sourced_from: ["inbox/archive/health/2026-03-20-kff-cbo-obbba-coverage-losses-medicaid.md"]
-- OBBBA Medicaid work requirements destroy the enrollment stability that value-based care requires for prevention ROI by forcing all 50 states to implement 80-hour monthly work thresholds by December 2026|supports|2026-04-09
+related: ["vbc-requires-enrollment-stability-as-structural-precondition-because-prevention-roi-depends-on-multi-year-attribution", "obbba-medicaid-work-requirements-destroy-enrollment-stability-required-for-vbc-prevention-roi"]
-sourced_from:
-- inbox/archive/health/2026-03-20-kff-cbo-obbba-coverage-losses-medicaid.md
 ---
 
 # Value-based care requires enrollment stability as structural precondition because prevention ROI depends on multi-year attribution and semi-annual redeterminations break the investment timeline
 
-The OBBBA introduces semi-annual eligibility redeterminations (starting October 1, 2026) that structurally undermine VBC economics. VBC prevention investments — CHW programs, chronic disease management, SDOH interventions — require 2-4 year attribution windows to capture ROI because health improvements and cost savings accrue gradually. Semi-annual redeterminations create coverage churn that breaks this timeline: a patient enrolled in January may be off the plan by July, transferring the benefit of prevention investments to another payer or to uncompensated care. This makes prevention investments irrational for VBC plans because the entity bearing the cost (current plan) differs from the entity capturing the benefit (future plan or emergency system). The CBO projects 700K additional uninsured from redetermination frequency alone, but the VBC impact is larger: even patients who remain insured experience coverage fragmentation that destroys multi-year attribution. This is a structural challenge to the healthcare attractor state, which assumes enrollment stability enables prevention-first economics.
+The OBBBA introduces semi-annual eligibility redeterminations (starting October 1, 2026) that structurally undermine VBC economics. VBC prevention investments — CHW programs, chronic disease management, SDOH interventions — require 2-4 year attribution windows to capture ROI because health improvements and cost savings accrue gradually. Semi-annual redeterminations create coverage churn that breaks this timeline: a patient enrolled in January may be off the plan by July, transferring the benefit of prevention investments to another payer or to uncompensated care. This makes prevention investments irrational for VBC plans because the entity bearing the cost (current plan) differs from the entity capturing the benefit (future plan or emergency system). The CBO projects 700K additional uninsured from redetermination frequency alone, but the VBC impact is larger: even patients who remain insured experience coverage fragmentation that destroys multi-year attribution. This is a structural challenge to the healthcare attractor state, which assumes enrollment stability enables prevention-first economics.
+
+## Extending Evidence
+
+**Source:** KFF Medicaid GLP-1 coverage analysis, January 2026
+
+State Medicaid coverage instability now extends beyond enrollment churn to coverage policy reversal. Four states eliminated GLP-1 obesity coverage in 2025-2026, meaning patients who began treatment under coverage may lose access mid-therapy. This policy-level instability compounds enrollment churn, further undermining the multi-year attribution required for prevention ROI in value-based care models.